Adaptive Biotechnologies Q3 Earnings Call Highlights
Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.
How this was made

The 30-second read
Why it matters
Revenue growth and guidance lift indicate expanding market share, but cash burn and Medicare pricing remain risks.
Market read
Earnings and guidance update provide fresh data for traders; likely catalyst for short‑term price movement.
What to watch
Potential Medicare pricing pressure and pending MolDX bundle decision could temper upside.
Background
Adaptive Biotechnologies provides clonoSEQ MRD testing for blood cancers; earnings reflect growing clinical and pharma demand.
Ticker impact
Q3 earnings disclosed $83.9M revenue, GAAP net income $2.8M and raised full-year MRD revenue guidance to $276-$286M.
potential upside as market prices in higher MRD revenue outlook
Guidance lift is a fresh, material update; investors typically reward higher revenue expectations.
Market effects
Positive for biotech firms with MRD testing platforms and related pharma partners.
U.S. biotech sector may see modest lift.
Limited to investors tracking precision‑medicine diagnostics.
Counterpoint
Guidance raise may be offset by higher operating expense expectations and lack of GAAP profit in Q4.
Key entities
- companyAdaptive Biotechnologies
Biotech firm offering clonoSEQ MRD testing.
- regulatory_bodyMolDX
Agency reviewing additional testing bundle request.


